

PLEOMORPHIC SKIN ERUPTIONS IN A COVID-19 AFFECTED PATIENT: CASE REPORT AND REVIEW OF THE LITERATURE

Scala Enrico, Fania Luca, Bernardini Filippo, Calarco Rodolfo, Chiloire Sabrina, Di Campi Cristiana, Erculei Sabrina, Giani Mauro, Giordano Marzia, Panebianco Annarita, Passarelli Francesca, Trovè Andrea, Verkhovskaia Sofia, Russo Giandomenico, Sgadari Antonio, Didona Biagio, Abeni Damiano

Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, via dei Monti di Creta 104, 00167, Rome, Italy

Corresponding Author: Enrico Scala. Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, via dei Monti di Creta 104, 00167, Roma, Italia. e-mail: e.scala@idi.it. Tel: +393487998657. Fax: +390666462010.

Text word count: 1755; **Figure:** 1; **Table:** 1 **References:** 25

Conflict of Interest Disclosure: none.

IRB Status Statement: not required.

Funding: This study was supported, in part, by the "Progetto Ricerca Corrente "of the Italian Ministry of Health, Rome, Italy.

Keywords: Viral exanthem, COVID, drug reaction, cutaneous reaction, skin, dermatology.

Dear Editor,

The coronavirus disease (COVID-19), initially appeared in Wuhan (China)[1], is due to an infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[2] often associated with a respiratory failure caused by severe interstitial pneumonia[3], and has currently reached a pandemic extent[4;5].

The disease, during its course, may involve several organs, including the skin with a petechial skin rash[6], urticaria and erythematous rash, or varicella-like eruption, representing an additional effect of the SARS-CoV-2 infection, as commonly observed in other viral diseases [7].

There is currently no specific treatment recommended for COVID-19 disease. Several medications are being explored such as dexamethasone[8], remdesivir[9], chloroquine, and hydroxychloroquine[10;11] (generally in combination with azithromycin), lopinavir-ritonavir[12], Janus kinase inhibitors (baricitinib)[13], monoclonal antibodies against the interleukin-6 receptor (tocilizumab and sarilumab)[14], SARS patient sera[15], non-steroidal anti-inflammatory drugs[16], angiotensin-converting enzyme 2[16], and anticoagulant therapy with heparin[17] scant or contrasting data are supporting the efficacy of any of these agents, to date[18]. Considering that symptomatic COVID-19 patients generally undergo multi-drug treatments, the occurrence of a possible adverse drug reaction (ADR) presenting with cutaneous manifestations should be contemplated.

We present the case of a 59-year-old Caucasian woman, affected by a stable form of Chronic lymphocytic leukaemia, admitted to the ER due to fever, cough, rhinorrhoea, and dyspnoea. A marked respiratory failure, bilateral air-space opacification on lung radiographs, and bilateral, symmetric areas of ground-glass attenuation on computed tomographic (CT) scans, were recorded. A nasopharyngeal swab specimen was collected and tested for SARS-CoV-2 RNA by Reverse Transcription Polymerase Chain Reaction (RT-PCR), yielding a positive result.

The patient was therefore treated with a combination of hydroxychloroquine sulphate (Plaquenil®), darunavir (Prezista®), ritonavir, monoclonal antibodies against the interleukin-6 receptor (Sarilumb®), omeprazole, ceftriaxone (Rocephin®), high-flow oxygen therapy devices (Venturi masks), and filgrastim (Zarzio®) as a single injection for neutropenia arising following antiviral therapy. She continued assuming enoxaparin 4000 I.U. twice a day.

About 20 days later, while respiratory function progressively improved, in the presence of a still positive nasopharyngeal swab, moderately itching widespread and coalescing papular and erythematous lesions with superimposed vesicle or crust, not associated with fever's recurrence, appeared on the trunk. In the following days, plaques and papules with erythematous pomphoid appearance emerged symmetrically on the trunk and limbs. Eventually, the same lesions became purple-coloured large patches and maculae symmetrically affecting the trunk and limbs, but sparing the armpits, always with a remarkable symmetry of the lesion (Figure 1A)

A punch biopsy for histological examination was obtained from the patient's back on day three, and hematoxylin-eosin stained tissue specimens showed the presence of ortho- and para-keratosis, rare intraepidermal necrotic keratinocytes, oedema of the papillary dermis and superficial perivascular and interstitial infiltrate (Fig 1C), consisting of CD3⁺CD5⁺ T lymphocytes, some of them CD30⁺, having a blastic appearance, very rare CD20⁺ B cells and exceptional CD79a⁺ plasma cells, numerous eosinophilic granulocytes, and scant neutrophilic granulocytes. Such histological findings were suggestive of polymorphic erythema, but the presence of numerous eosinophilic granulocytes was indicative of toxidermic reactions (Fig 1D). Flow cytometric immunophenotyping of peripheral blood lymphocytes confirmed the presence of 94.5% (19,781/ μ l) CD19⁺ B cells, 87.6% of them bearing the T cell marker CD5⁺, aberrantly and commonly expressed in B cell chronic lymphocytic leukaemia (Fig 1B). As a consequence, a clear reduction of all the other subsets (CD3⁺ = 3.6%, 412/ μ l; CD3⁺CD4⁺ = 2.4%, 272/ μ l; CD3⁺CD8⁺ = 1.1%, 130/ μ l; and

CD3⁺CD16⁺CD56⁺ = 0.7%, 74/ μ l) was observed. T cell receptor-V β analysis identified no impairment of the T cell repertoire [19;20].

The patient received a high-dose Desametasone (Soldesam®) therapy for 5 days with gradual tapering of dosage for further two weeks. The patient resulted negative to the SARS-CoV-2 nasopharyngeal swab a week after the rash onset.

Two months later, after obtaining the patient's written consent, an allergy study was carried out for β -lactam reactivity. Skin tests were done by prick, and since negative results were recorded, the intradermal test were performed. The determinants and maximum concentration used were: benzylpenicilloyl polylysine (BPO) (Allergopen, Reinbek, Germany) [5x10⁻⁵ mM/l], a minor determinant mixture containing benzylpenicillin and benzylpenicilloate (Allergopen) [2x10⁻² mM/l], penicillin-G [10.000 UI/ml], and a panel of cephalosporins, including Ceftriaxone [all at 2mg/ml]. The patient's serum was tested for the presence of specific IgE to penicilloyl G, penicilloyl V, ampicilloyl, amoxicilloyl, and cefaclor (UniCAP specific IgE; Pharmacia & Upjohn, Uppsala, Sweden). We also performed patch tests with cephalosporins as previously described[21]. All tests were negative, and the patient refused a challenge test with ceftriaxone as well as a further investigation with the other possible culprit drugs.

Several clinical dermatologic presentations could occur during an ADR, including varicella or morbilliform-like exanthema, urticaria, erythema multiformis, vasculitis reaction with petechial and purpuric lesions, acral ischemia, and livedo reticularis. Since COVID-19 could present with all these clinical manifestations, a differential diagnosis between the infectious disease and ADR should be reached. Furthermore, it should be taken into account that many of the symptomatic COVID-19 patients are elderly individuals who assume several drugs to control various pre-existing conditions, thus increasing the risk of ADR.

In table 1 we differentiate an exanthem triggered by the viral Sars-CoV-2 infection from an ADR through the evaluation of clinical, serological, and histological parameters. Marzano et al. reported that the COVID-19 exanthem appeared 3 days after systemic symptoms and disappeared after 8 days, without facial or mucosal involvement[22]. In the reported cases of COVID-19 infection, the itch was mild or absent and cutaneous lesions interested mainly the trunk[7;22]. Considering laboratory parameters in COVID-19 disease, elevated levels of lactate dehydrogenase, ferritin, and aminotransferase have been described. Furthermore, high D-dimer levels and more severe lymphopenia have been associated with higher mortality[23], whilst, on the other hand, atopic status was associated with less severe clinical outcomes[24]. In case of doubts regarding the cause of the rash, a biopsy would be necessary to confirm the diagnosis. Histological examination of the viral exanthema shows a slightly atrophic epidermis with basket-weave hyperkeratosis and vacuolar degeneration of the basal layer with enlarged and multinucleate keratinocytes, without lymphomonocytic infiltrate. Otherwise, ADRs present histologically with an interface dermatitis characterized by spongiosis and superficial, or superficial and deep, perivascular and interstitial infiltrate of lymphocytes and eosinophils, sometimes with scanty neutrophils; vacuolar changes at the dermo-epidermal junction with necrotic keratinocytes can often be observed[25]. However, the histological examination can also be difficult to interpret, as the appearance of viral lesions and ADR may be quite similar. Besides, it must be remembered that in some cases ADRs occur in conjunction with a viral infection, as it happens for example in the morbilliform exanthema due to taking ampicillin during an EBV infection, or in the DRESS syndrome where there is a reactivation of HHV-6.

It is very important to correctly identify the two different etiological situations since they require diverging treatment approaches. In fact, in case of COVID-19 disease, it would be justified to continue the multi-drug antiviral treatment, while in case of ADR it would be necessary to

identify the possible culprit drug, to stop as soon as possible the administration of that drug, and to start appropriate treatment (glucocorticoid and/or antihistamine drug).

AUTHORS CONTRIBUTIONS: ES and FL conceived the study, and wrote the manuscript. BF, CR, CS, DiC, ErS, GM, PA, TA, VS, RG, PA and SA cared for Covid-19 patient and provided the clinical data. FP and BD performed histological evaluation. DA performed the statistical analysis and wrote the manuscript.




Figure 1. [A] Day by day clinical evolution of skin lesions. *Day one:* widespread and coalescing popular and erythematous lesions with superimposed vesicle or crust are present on the trunk. *Day two:* plaques and papules with erythematous pomphoid appearance are arranged symmetrically on the trunk and limbs. *Day three:* flat and erythematous-violaceous plaques and papules are located symmetrically on the trunk and limbs. *Day four:* purple-coloured large patches and maculae symmetrically affect the trunk and limbs. *Day five:* the skin of the trunk and the root of the limbs is oedematous and purplish; the skin of the armpits is spared; the symmetry of the lesion is once again remarkable. *Day six:* the skin of the trunk and the root of the limbs is moderately erythematous; the skin of the armpits is spared. *Day ten:* skin lesions are healing: post-lesional peeling and mild erythema are noted.

[B] FACS analysis on PBMC showing the four-colour flow cytometry of CD19/CD5/CD3/CD4/CD8 combination. CD45⁺ live lymphocytes were gated on forward and side light scatter. *B.1* shows the aberrant overexpression of CD5 by the vast majority of circulating neoplastic CD19⁺ B cells. *B.2* shows the CD3⁺CD4⁺ and CD3⁺CD8⁺ distribution in the peripheral blood.

[C] Hematoxylin and eosin staining. *C.1* = Ortho- and para-keratosis, modest oedema of the papillary dermis with initial dermo-epidermal detachment and superficial infiltrate mainly peri-vascular (original magnification x5); *C.2* = Vacuolar alteration of the dermo-epidermal junction with lymphocyte infiltrate. Presence of some intraepidermal necrotic keratinocytes. In the papillary dermis, there are extravasated red cells and infiltrated lymphocytes, eosinophilic and neutrophilic granulocytes and some lymphoid blasts (original magnification x20). *C.3* = Detail of the infiltrate already described in *C.2* showing the presence of red blood cells, lymphocytes, neutrophilic and eosinophilic granulocytes, blasts (original magnification x40). *C.4* = Another detail showing mainly Eosinophilic granulocytes infiltrate (original magnification x40).

[D] Immunohistochemistry for CD3 (*D.1*), CD5 (*D.2*) and CD30 (*D.3*) showing that most of the infiltrate in the inflamed skin biopsy is represented by CD3⁺ and CD5⁺ T lymphocytes, some of them activated and therefore expressing CD30. Original magnification: x40.

	Viral Exanthem (Sars-CoV-2 infection)	Exanthem in Adverse drug reactions
Onset of cutaneous manifestation ^a	<10 days	1->10 days
Respiratory, gastro-intestinal or other symptoms ^b	+	-
Multidrug therapy	-	+
Symmetric distribution of cutaneous lesions	-	+
Facial or mucosal involvement	-	+
Itch ^c	-	+
Eosinophilia	-	+
Lymphopenia	+	-
Increased Total IgE	-	+/-
Increased LDH, ferritin and D-dimer	+	-
Histology of cutaneous lesions ^d	Viral reaction	Drug reaction

^a Compared to other clinical manifestation or main symptoms of COVID-19 infection

^b Fever, cough, rhinorrhea, dyspnea, nausea and diarrhoea, headaches, myalgia, weakness, coryza, hyposmia, hypogeusia, pharyngodynia

^c In Covid-19 infection has been reported no or mild itch

^d See description in the text

Reference List

1. Ng OT, Marimuthu K, Chia PY, Koh V, Chiew CJ, De WL et al. SARS-CoV-2 Infection among Travelers Returning from Wuhan, China. *N Engl J Med* 2020; 382:1476-1478.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; 382:727-733.
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020; 382:1199-1207.
4. Kottner JA, Tugwell P. Methodological challenges in studying the COVID-19 pandemic crisis. *J Clin Epidemiol* 2020; 121:A5-A7.
5. Jewell NP, Lewnard JA, Jewell BL. Predictive Mathematical Models of the COVID-19 Pandemic: Underlying Principles and Value of Projections. *JAMA* 2020.
6. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. *J Am Acad Dermatol* 2020; 82:e177.
7. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol* 2020.
8. Johnson RM, Vinetz JM. Dexamethasone in the management of covid -19. *BMJ* 2020; 370:m2648.

9. Maciorowski D, Idrissi SZE, Gupta Y, Medernach BJ, Burns MB, Becker DP et al. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. *SLAS Discov* 2020;2472555220958385.
10. Ortolani C, Pastorello EA. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost? *Clin Mol Allergy* 2020; 18:17.
11. Vinetz JM. Lack of efficacy of hydroxychloroquine in covid-19. *BMJ* 2020; 369:m2018.
12. Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. *CMAJ* 2020; 192:E734-E744.
13. Praveen D, Puvvada RC, VA M. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. *Int J Antimicrob Agents* 2020; 55:105967.
14. Douedi S, Chaudhri M, Miskoff J. Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19. *Ann Thorac Med* 2020; 15:171-173.
15. Anderson DE, Tan CW, Chia WN, Young BE, Linster M, Low JH et al. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. *Emerg Microbes Infect* 2020; 9:900-902.
16. Smart L, Fawkes N, Goggin P, Pennick G, Rainsford KD, Charlesworth B et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. *Inflammopharmacology* 2020; 28:1141-1152.
17. Gozzo L, Viale P, Longo L, Vitale DC, Drago F. The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review. *Front Pharmacol* 2020; 11:1307.
18. Paumgartten FJR, Oliveira ACAX. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. *Cien Saude Colet* 2020; 25:3413-3419.
19. Scala E, Russo G, Cadoni S, Narducci MG, Girardelli CR, De PO et al. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion. *J Invest Dermatol* 1999; 113:622-627.
20. Scala E, Narducci MG, Amerio P, Baliva G, Simoni R, Giovannetti A et al. T cell receptor-Vbeta analysis identifies a dominant CD60+. *J Invest Dermatol* 2002; 119:193-196.
21. Scala E, Giani M, Pastore S, Pallotta S, Guerra EC, Pirrotta L et al. Distinct delayed T-cell response to beta-methasone and penicillin-G in the same patient. *Allergy* 2003; 58:439-444.
22. Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. *J Am Acad Dermatol* 2020.

23. Ou M, Zhu J, Ji P, Li H, Zhong Z, Li B et al. Risk factors of severe cases with COVID-19: a meta-analysis. *Epidemiol Infect* 2020; 148:e175.
24. Scala E, Abeni D, Tedeschi A, Manzotti G, Yang B, Borrelli P et al. Atopic status protects from severe complications of COVID-19. *Allergy* 2020.
25. Weyers W, Metze D. Histopathology of drug eruptions - general criteria, common patterns, and differential diagnosis. *Dermatol Pract Concept* 2011; 1:33-47.